Xylyx Bio and Cell & Soft Announce positive initial results following Strategic Partnership to Develop Next-Generation in vitro Platforms to Accelerate Cancer Drug Discovery

Xylyx Bio and Cell & Soft Announce positive initial results following Strategic Partnership to Develop Next-Generation in vitro Platforms to Accelerate Cancer Drug Discovery

New York-based Xylyx Bio, a leader in predictive disease models and tissue-specific extracellular matrix (ECM) products, and Cell&Soft SAS, a French biotech company specializing in innovative soft cell culture plates, today announced positive preliminary results, reaching a key milestone in their partnership to develop more physiologically relevant in vitro cellular models for cell-based assays in oncology. Read more >>

Share this post